Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Ambroxol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.94 |
| ▸ | GBA1 | P04062 | 1/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.94 |
| ▸ | HRH2 | P25021 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL423712 | 0.97 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL18702 | 0.97 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL7855003 | 0.97 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL28472066 | 0.97 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL29380194 | 0.97 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL99455 | 0.96 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL6601413 | 0.96 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL11533052 | 0.91 | CYP2D6 (0.87) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL24446418 | 0.89 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL22927201 | 0.89 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3996696-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | Genethon (FR) | 2022-05-18 | — | — | EP | claimed |
| WO-2021005176-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | GENETHON (FR) | 2021-01-14 | — | — | WO | claimed |
| CN-115212173-B | Ambroxol hydrochloride spherical slow-release particles, preparation method and application | 上海现代药物制剂工程研究中心有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-116077430-A | Ambroxol oral solution | 江苏广承药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110870854-B | Ambroxol solution preparation for inhalation and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-115212173-A | Ambroxol hydrochloride spherical sustained-release particles, preparation method and application | 上海现代药物制剂工程研究中心有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220331408-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | GENETHON (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3996696-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | Genethon (FR) | 2022-05-18 | — | — | EP | disclosed |
| CN-110200905-B | Ambroxol hydrochloride composition, injection and application thereof | 黑龙江珍宝岛药业股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114042038-A | Ambroxol hydrochloride oral solution | 江苏汉晨药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-113633607-A | Pharmaceutical composition containing ambroxol hydrochloride and preparation method thereof | 北京四环科宝制药有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021005176-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | GENETHON (FR) | 2021-01-14 | — | — | WO | disclosed |
| CN-110870854-A | Ambroxol solution preparation for inhalation and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3566700-A1 | AMBROXOL FOR DNA DAMAGE REPAIR DISEASE THERAPIES | Universitat Autònoma de Barcelona (ES) | 2019-11-13 | — | — | EP | disclosed |
| CN-106478524-B | A kind of preparation method of ambroxol hydrochloride impurity standard items | 合肥久诺医药科技有限公司 | 2018-09-11 | — | — | CN | disclosed |
| CN-106478524-A | A kind of preparation method of ambroxol hydrochloride impurity standard substance | 合肥久诺医药科技有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |